ViiV Healthcare UK (No. 4) Ltd., a subsidiary of GSK Plc, is a company headquartered in Middlesex, UK, that engages in development, enhancement, maintenance, protection and exploitation of intellectual property assets. It was founded in 2015.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company’s discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.

The Board of Trustees of the University of Illinois, part of University of Illinois, is a company headquartered in Urbana, IL, that trusts Except Educational Religious.

Dabur Research Foundation (DRF) is an Indian contract research organization offering pre-clinical services in drug discovery and development. It was established in 1979 to spearhead the research and development activities of Dabur, India's largest Ayurvedic medicine manufacturer.

Dabur Pharma Ltd. manufactures and markets oral and injectable dosage forms and active pharmaceutical ingredients and intermediates. It work for cancer research and anticancer products. It markets products in the cardiovascular, antibacterial, antidiabetic & digestive segments. It markets its products in India, Nepal, Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Cyprus, Russia, Ukraine, Belarus, Georgia, Hungary, Kenya, Nigeria, Ghana, Zimbabwe, Brazil, Colombia, Venezuela, Peru, Costa Rica, Mexico, Barbados and Jamaica. Incorporated in 2003, Dabur Pharma Ltd. is headquartered in New Delhi, India with offices in the UK, Malaysia and Russia. Offices are also being set up in Thailand, Philippines and Brazil.

The Nisshin OilliO Group, Ltd. engages in the manufacture, processing, and distribution of edible oils. It operates through the following segments: Oils and Fats, Modified Fats, Fine Chemicals, Healthy Food and Others. The Oils and Fats segment manufactures and supplies edible oil products for home use, commercial purpose, and food processing. The Modified Fats segment manufactures and supplies modified fats and chocolates. The Fine Chemicals segment manufactures and supplies cosmetic raw materials and chemical substances. The Healthy Food segment manufactures and supplies dressings and mayonnaise. The Others segment deals with temporary staffing, insurance agency, and golf driving range and equipment rental businesses. The company was founded by Kihachiro Okura and Kyujiro Matsushita on February 22, 1907 and is headquartered in Tokyo, Japan.

Novelix Pharmaceuticals, Inc. (Novelix), is a private, La Jolla based, biotechnology company committed to developing innovative, proprietary, dermatology products with large market potential to treat serious skin diseases. The company's main focus is the development of NVX-207, a novel, topical drug candidate with the potential to revolutionize how actinic keratosis (AK) is being treated in the absence of inflammation. AK is a pre-cancerous skin condition resulting from prolonged sun exposure and is one of the the skin diseases most frequently diagnosed by US dermatologists, affecting more than 60 million Americans. In Australia, for instance, AK affects about half the population over age 50. While the overall AK market is estimated at over $2 billion in the US alone, topical therapy is used in only about 25% of patients due to limited activity (complete clearance of lesions in only about half the patients) and often severe side effects of available topical products. In spite of these deficiencies, the AK market for topical products in the US alone exceeded $450 million in 2009 growing at 22% per annum. NVX-207's patent position is strong, development timelines to human proof of concept in AK patients are short and interest in the opportunity at the proof of concept level is clear. A recent transaction demonstrates the interest in new therapies in AK markets - LEO Pharma of Denmark acquired Peplin for $287.5 million in cash to gain access to PEP005, a natural product, without composition of matter patent protection and average to low activity, in late stage development for AK. NVX-207's potential in additional large-market dermatology opportunities including genital warts, a second small molecule NCE program and a full pipeline complement the Novelix product portfolio.

Stora Enso Oyj (Swedish: Stora [stuːra] and Finnish: Enso [enso]) is a manufacturer of pulp, paper and other forest products, headquartered in Helsinki, Finland. The majority of sales takes place in Europe, but there are also significant operations in Asia, South America and the United States. Stora Enso was formed in 1998, when the Swedish mining and forestry products company Stora AB merged with the Finnish forestry products company Enso Oyj. In 2018, the average number of employees was 26 000. For 2015, Stora Enso was ranked seventh in the world by sales and fourth by earnings, among forest, paper and packaging industry companies. For the first two quarters of 2018, the company was ranked second by net earnings among European forest and paper industry companies. The corporate history can be traced back to the oldest known preserved share certificate in the world, issued in 1288. Based on this, some observers consider Stora Enso to be the oldest limited liability company in the world.

Myrexis, Inc. is in the process of evaluating strategic alternatives, including focusing on identifying, evaluating, and making financial investments in life sciences assets. The company was founded in January 2009 and is headquartered in New York, NY.

Advanced Life Sciences Holdings, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of drugs in the areas of infectious disease, oncology and respiratory disease. The Company has assembled a pipeline of clinical and preclinical product candidates. The Company has a worldwide license (excluding Japan) from Abbott Laboratories (Abbott) to develop and commercialize cethromycin, once-a-day antibiotic for the treatment of respiratory tract infections.

Jinan Haoyu Qingtian Pharmaceutical Technology Co., Ltd., established on 2016-04-19, The scope of business includes the development of medical technology,technical consulting;Wholesale of prepackaged food;biology,Sales of pharmaceutical products;Healthy food,cosmetic,medical instruments,Chemical Products(Free of Hazardous Chemicals),Technology Development of Traditional Chinese Medicine,technology transfer,technical consulting,Technical Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Pola Chemical Industry, Inc. provides cosmetic products, chemicals doranidazole, and pola cosmetics. The company is headquartered in Shinagawa-Ku, Japan.

Unilever NV engages in the production and marketing of consumer goods in the nutrition, hygiene, and personal care categories. It operates through the following segments: Beauty and Personal Care, Foods and Refreshment, and Home Care. The Beauty and Personal Care segment covers the sales of skin and hair care products, deodorants and oral care products. The Foods and Refreshment segment includes the sales of soups, bouillons, sauces, snacks, mayonnaise, salad dressings, margarines and spreads. The Home Care segment is in charge of the sales of home care products such as powders, liquids and capsules, soap bars, and a wide range of cleaning products. The company was founded on November 9, 1927 and is headquartered in Rotterdam, Netherlands.

Unilever Plc engages in the manufacture and sale of consumer goods. It operates through the following segments: Beauty & Wellbeing, Personal Care, Home Care, Nutrition, and Ice Cream. The Beauty & Wellbeing segment offers hair care, skin care, and prestige beauty and health & wellbeing. The Personal Care segment consists of sales of skin cleansing, deodorant, and oral care products. The Home Care segment comprises of sales of fabric care and a wide range of cleaning products. The Nutrition segment refers to sales of scratch cooking aids, dressings, and tea products. The Ice Cream segment covers primarily ice cream products. The company was founded by Antonius Johannes Jurgens, Samuel van den Bergh, and William Hulme Lever on January 1, 1930 and is headquartered in London, the United Kingdom.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Oy Granula Ab Ltd. (doing business as Oy Granula Ab Ltd.) is a Finnish private company located in Kotka that provides cosmetic and sun protection products. The firm was founded in 1997 by John Thomas Alhnas. Johannes Arne Erik Ahlnäs is the current CEO, occupying that position since 2009.\nThe company says this about itself: Oy Granula Ab Ltd develops, manufactures and refines chemical products and markets them for industries world-wide. We also provide measurement services and assistance in your product development. Our aim is to develop and manufacture products for the cosmetics industry that are beneficial to public health as well as easy and safe to use.

Korea Institute of Energy Research is a government-funded research institute that develops energy technology.